<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744207</url>
  </required_header>
  <id_info>
    <org_study_id>GS-2001</org_study_id>
    <nct_id>NCT04744207</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis</brief_title>
  <official_title>A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesynta Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesynta Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety, and evaluate the efficacy of&#xD;
      GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the safety, and evaluate the efficacy of&#xD;
      GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).&#xD;
&#xD;
      This is a randomized, double-blind, placebo-controlled study conducted in multiple sites in 4&#xD;
      countries in Europe. Approximately 80 subjects will be randomized in a 1:1 allocation to&#xD;
      receive either GS-248 (120 mg) or placebo once daily. The study will comprise an enrolment&#xD;
      period, a treatment period, and a follow-up period, with a total of 5 study visits over&#xD;
      approximately 10 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline to week 4 in the number of Raynaud attacks per week.</measure>
    <time_frame>Daily from Day -7 to Day 28</time_frame>
    <description>Patient reported number of Raynaud's attacks per day as registered in electronic diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline to week 4 in the Raynaud's Condition Score.</measure>
    <time_frame>Daily from Day -7 to Day 28</time_frame>
    <description>Patient reported Raynaud's Condition Score each day as registered in electronic diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline to week 4 in the cumulative duration of Raynaud attacks.</measure>
    <time_frame>Daily from Day -7 to Day 28</time_frame>
    <description>Patient reported duration of Raynaud's attacks per day as registered in electronic diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline to week 4 in pain experienced during Raynaud attacks.</measure>
    <time_frame>Daily from Day -7 to Day 28</time_frame>
    <description>Patient reported pain of each Raynaud attack using Numeric Rating Scale as registered in electronic diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Daily from Day 1 to Day 42-49</time_frame>
    <description>Frequency, severity and seriousness of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in peripheral blood flow in fingers</measure>
    <time_frame>Day 1 at pre-dose and 2 hours post dose and Day 28 at pre dose</time_frame>
    <description>Peripheral blood flow will be measured with thermography assessments before and after cold challenge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>GS-248</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-248, capsule, 120 mg, once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, capsule, once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-248</intervention_name>
    <description>120 mg, capsule, once daily for 4 weeks</description>
    <arm_group_label>GS-248</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsule, once daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must provide signed and dated written informed consent before the conduct of&#xD;
             any study-specific procedures.&#xD;
&#xD;
          -  Male and female subjects aged 18-75 years inclusive.&#xD;
&#xD;
          -  Systemic Sclerosis diagnosed according to European League Against Rheumatism&#xD;
             (EULAR)/American College of Rheumatology (ACR) criteria (van den Hoogen F et al.&#xD;
             2013). Subjects with signs of other autoimmune diseases (e.g. Sjögren's syndrome,&#xD;
             myositis, rheumatoid arthritis) could be included if SSc is the dominating phenotype.&#xD;
&#xD;
          -  Raynaud attacks typically ≥7 times per week during the last 4 weeks prior to screening&#xD;
             despite background medication (only allowed vasodilatory therapy is calcium channel&#xD;
             blockers or PDE-5 inhibitors).&#xD;
&#xD;
          -  Women of childbearing potential must be using a highly effective method of&#xD;
             contraception to avoid pregnancy throughout the study and for 4 weeks after the last&#xD;
             dose of Investigational Medicinal Product in such manner that the risk of pregnancy is&#xD;
             minimised.&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding.&#xD;
&#xD;
          -  Male subjects to agree to use condom in combination with use of contraceptive methods&#xD;
             with a failure rate of &lt;1% to prevent pregnancy and drug exposure of a partner, and&#xD;
             refrain from donating sperm from the first date of dosing until 3 months after last&#xD;
             dosing of the IMP.&#xD;
&#xD;
          -  Ability of subjects to participate fully in all aspects of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic Sclerosis disease duration of greater than 120 months from first non-Raynaud&#xD;
             manifestation&#xD;
&#xD;
          -  Current smokers or stopped smoking &lt;3 months prior to Visit 1.&#xD;
&#xD;
          -  Dose-change or initiation of vasodilating substances (calcium blockers or PDE-5&#xD;
             inhibitors) within 4 weeks prior to Visit 1.&#xD;
&#xD;
          -  Use of iloprost or other intravenous (iv) or po prostacyclin receptor agonist within 4&#xD;
             weeks prior to Visit 1.&#xD;
&#xD;
          -  Ongoing treatment with immunosuppressive therapies (other than mycophenolate)&#xD;
             including, but not restricted to; cyclophosphamide, azathioprine, methotrexate, or&#xD;
             cyclosporine, or use of those medications within 4 weeks of trial entry.&#xD;
&#xD;
          -  Use of systemic corticosteroids during 4 weeks before screening and during the course&#xD;
             of the study.&#xD;
&#xD;
          -  Concurrent serious medical condition, with special attention to cardiovascular&#xD;
             conditions, which in the opinion of the Investigator makes the subject not suitable&#xD;
             for this study.&#xD;
&#xD;
          -  Prolonged QTcF interval defined as a mean QTcF &gt;450 msec.&#xD;
&#xD;
          -  Creatinine clearance &lt;50 mL/min (determined by Cockcroft-Gault equation) at Screening.&#xD;
&#xD;
          -  Active digital ulcer (DU) within 4 weeks prior to Visit 1.&#xD;
&#xD;
          -  Clinically meaningful laboratory abnormalities at Screening (Visit 1), as determined&#xD;
             and documented by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Edenius</last_name>
    <role>Study Director</role>
    <affiliation>Gesynta Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Edenius</last_name>
    <phone>+46 73 386 4246</phone>
    <email>ctg@gesynta.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ctg@gesynta.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

